RetinAD 1.0

Non-Invasive, AI-Powered Brain Health Triage Tool

RetinAD 1.0 uses state-of-the-art artificial intelligence to analyze retinal images, providing a critical, non-invasive first step in brain health assessment. This innovative tool serves as an effective triage mechanism, identifying individuals who may benefit from further in-depth evaluations, including those who need more invasive and costly diagnostic tests.

Precision in Early Detection and Risk Factor Identification

Our platform leverages sophisticated AI algorithms trained on a vast, multi-ethnic dataset of over 16,000 retinal images. RetinAD 1.0 achieves high specificity (90%) and sensitivity (94%) in distinguishing between Alzheimer’s dementia and cognitive normal subjects. Additionally, it identifies cognitively normal individuals who exhibit poorer control over modifiable risk factors associated with Alzheimer’s, facilitating early further assessment and interventions. These capabilities are validated through robust internal and external tests, ensuring reliable assessments for guiding further actions.

Empowering Primary Prevention and Public Health

Early detection and subsequent management of Alzheimer’s risk factors can significantly impact public health, potentially preventing up to 40% of dementia cases through optimized lifestyle and risk factor control. By pinpointing individuals at risk, RetinAD 1.0 not only facilitates timely medical referrals but also plays a pivotal role in primary prevention. It identifies those with suboptimal control of Alzheimer’s dementia (AD) modifiable risk factors, such as hypertension, diabetes, and lifestyle habits.

Strategic Partnerships for Enhanced Reach and Impact

Through strategic alliances with leading retinal camera manufacturers and healthcare organizations, RetinAD 1.0 is integrated into diverse medical settings, from local clinics and specialized centers, to global screening initiatives. These partnerships ensure widespread deployment and usability of our tool, maximizing its impact on global health.

Societal and Economic Benefits

RetinAD 1.0 not only streamlines the process of identifying those in need of further diagnostic attention but also enhances public health by facilitating better management of AD risk factors. This proactive approach reduces the need for extensive medical interventions later, decreasing the caregiving burden and associated economic costs. Moreover, by preventing potential cases of dementia through lifestyle adjustments and risk management, RetinAD 1.0 contributes to substantial long-term societal benefits.

Cloud-Based Accessibility and Seamless Integration

RetinAD 1.0 operates on a cloud-based SaaS platform, enhancing its scalability and ease of integration into existing healthcare systems worldwide. This ensures that the tool is accessible to healthcare professionals and individuals alike, enabling real-time, efficient brain health assessments. Future mobile app integration further supports ongoing monitoring and ease of access, making it practical for continuous health management.